Currently, out of the existing stock ratings of Tazeen Ahmad - 104 which are a Buy (57.14%), 54 which are a Hold (29.67%), 24 which are a Sell (13.19%)

Tazeen Ahmad

Work Performance Price Targets & Ratings Chart

Analyst Tazeen Ahmad works at BAML and is covering Healthcare, Industrials sectors with 367 price targets and ratings displayed on 36 stocks.

Tazeen Ahmad's average stock forecast success ratio is 63.54% with an average time for price targets to be met of 135.2 days.

Most recent stock forecast was given on PTCT, PTC Therapeutics at 19-Sep-2023.

Wall Street Analyst Tazeen Ahmad

Analyst best performing recommendations are on RYTM (RHYTHM PHARMACEUTICALS).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 7/31/2023. The price target of $22 was fulfilled within 1 day with a profit of $4.16 (23.32%) receiving and performance score of 233.18.

Average potential price target upside

of $32.94 (13.18%) on ARGX (ARGENX SE).
of $31.36 (24.66%) on GWPH.
of $22.16 (29.92%) on NBIX (NEUROCRINE BIOSCIENCES).

ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BNTX BioNTech SE Sponsored ADR FOLD Amicus Therapeutics FULC GRTX Galera Therapeutics GWPH INCY yte NBIX Neurocrine Biosciences PRLD Prelude Therapeutics PTCT PTC Therapeutics RARE Ultragenyx Pharmaceutical RYTM Rhythm Pharmaceuticals SAGE Sage Therapeutics ASND Ascendis Pharma A/S CRTX Cortexyme ORPH Orphazyme A/S Unsponsored ADR SRPT Sarepta Therapeutics BCRX BioCryst Pharmaceuticals PRTA SRZN TBPH Theravance Biopharma ADCT FATE Fate Therapeutics ADMS Adamas Pharmaceuticals AKUS ARGX argenx SE CLVS Clovis Oncology CYT ETN Eatonplc KALA Kala Pharmaceuticals MCRB Seres Therapeutics PYXS SGEN Seattle Genetics SQZ SQZ Biotechnologies Company ZGNX Zogenix

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Jeffrey Hung (MORGAN STANLEY)